Deal of the Day — limited-time pharmacy picks!
Enzamide 40mg Capsule

Enzamide 40mg Capsule

Prescription requiredRx Required

Salt Composition: Enzalutamide

Expiry Date: 01/2028

Special offer

Buy at $202.94

$202.94

Inclusive of all taxes

▼

28 Capsule(s) In A Strip

About The Product

​Prostate cancer​

Description

Enzamide 40mg Capsule is a target therapy based chemotherapeutic medication.It is used to treat Metastatic and Non-Metastatic castration-resistant Prostate Cancer. Enzamide 40mg Capsule contains Enzalutamide salt that works by inhibiting the androgen receptors.As a result, this medication inhibits male hormone driven cancer progression.

This medication can only be purchased after a doctor's prescription.

Dosage And Administration

  • The typical prescribed dosage of Enzamide 40mg Capsule is 160mg daily.
  • It means patient need to consume 4 capsules daily.
  • This medicine is taken orally with the help of water.
  • Avoid breaking, chewing, biting of capsules to maintain its integrity and efficacy.
  • To know about exact dosage and treatment time, visit your doctor for consultation.

Mechanism Of Action

Enzamide 40mg Capsule contains Enzalutamide salt that works by inhibiting the androgen receptors. Androgen receptors are responsible for testosterone hormone production.

Blocking of androgen receptor reduces the testosterone hormone that helps in cancer cell growth and proliferation.As a result, this medication inhibits male hormone driven cancer progression. This medication can only be purchased after a doctor's prescription.

Faqs

Enzamide 40mg Capsule is used to treat Metastatic and Non-Metastatic castration-resistant Prostate Cancer.

References

• Beer, T. M., Armstrong, A.

J., Rathkopf, D. E., Loriot, Y., Sternberg, C.

N., Higano, C. S., ... & Tombal, B.

(2014). Enzalutamide in metastatic prostate cancer before chemotherapy.

New England Journal of Medicine, 371(5), 424-433. • Davis, I. D., Martin, A.

J., Stockler, M. R., Begbie, S., Chi, K.

N., Chowdhury, S., ... & Sweeney, C. J.

(2019). Enzalutamide with standard first-line therapy in metastatic prostate cancer.

New England Journal of Medicine, 381(2), 121-131. • Claessens, F., Helsen, C., Prekovic, S., Van den Broeck, T., Spans, L., Van Poppel, H., & Joniau, S. (2014).

Emerging mechanisms of enzalutamide resistance in prostate cancer. Nature reviews urology, 11(12), 712-716. • Moreira, R.

B., Debiasi, M., Maluf, F. C., Bellmunt, J., Fay, A.

P., Choueiri, T. K., & Schutz, F.

A. B.

(2016). Differential side effects profile in mCRPC patients treated with abiraterone or enzalutamide: A meta-analysis of randomized controlled trials.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026